Arca Biopharma reported $53.36M in Cash and Equivalent for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Amgen AMGN:US $ 5203M 1325M
Arca Biopharma ABIO:US $ 53.36M 13.57M
Biogen BIIB:US $ 2646.6M 897.3M
Brainstorm Cell Therapeutics BCLI:US $ 9.01M 6.15M
Bristol Myers Squibb BMY:US $ 10750M 1619M
Capricor Therapeutics CAPR:US $ 51.42M 6.92M
Cytokinetics CYTK:US $ 93.63M 21.79M
Cytrx CYTR:US 5.08M 1.69M
Daiichi Sankyo 4568:JP Y 658064M 4413M
Gilead Sciences GILD:US $ 7000M 2704M
GlaxoSmithKline GSK:LN 6465M 4502M
Laboratory Of America LH:US $ 1068.8M 164.7M
Myriad Genetics MYGN:US $ 24.1M 3.1M
Otsuka Holdings 4578:JP Y 456759M 33397M
United Therapeutics UTHR:US $ 795.2M 18.1M